Jeff received his B.S in Molecular Biophysics and Biochemistry from Yale University and Ph.D in Cell Biology under the late Dr. Günter Blobel from Rockefeller University.  He completed his postdoctoral fellowship in molecular genetics and oncology in the Molecular Biology Department at Princeton University.

Jeff’s career in pharmaceutical research and development began at Merck in computational biology and transitioned to regulatory affairs.  From Merck, Jeff continued in regulatory affairs at Otsuka Pharmaceutical and Development Corporation, Sun Pharma Advanced Research Company (SPARC) and Roivant Sciences, Inc.  During this time, Jeff’s role in regulatory affairs expanded and included building the regulatory affairs department and being the Head and Vice President of Global Regulatory Affairs at SPARC and later at Roivant.  Under his leadership, he led the approval of 8 drugs globally, 20 INDs and 30+ CTAs globally, 48+ global regulatory agency meetings, and 20+ due diligences. His experience spans all phases of development from early to post approval and includes small molecules, biologics, and drug/device combination products.

During Jeff’s 30+ year experience in drug development, he has supported programs in multiple therapeutic areas, which include cardiovascular, oncology, rheumatology, psychiatry, gastrointestinal, pulmonology, neurology, dermatology and ophthalmology.  This has allowed him to develop a broad and nuanced view of the requirements and expectations for the regulatory aspects of drug development.